E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Non-Curable Squamous cell carcinoma of the head and neck (SCCHN) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060121 |
E.1.2 | Term | Squamous cell carcinoma of head and neck |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To investigate if HuMax-EGFr in combination with Best Supportive Care (BSC) is superior to BSC in terms of overall survival in non-curable patients with recurrent and/or metastatic disease who have failed at least one course of standard platinum-based chemotherapy |
|
E.2.2 | Secondary objectives of the trial |
To compare HuMax-EGFr in combination with BSC to BSC with respect to efficacy, safety and Quality of Life (QoL) and to determine the pharmacokinetic profile of HuMax-EGFr |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Males and Females age ≥ 18 years
2) Histologically or cytologically confirmed diagnosis, initially or at relapse, of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, considered incurable with standard therapy.
3) Failure to at least one course of standard platinum-based chemotherapy.
One course of standard platinum-based chemotherapy is defined as at least two cycles of cisplatin ( 60 mg/m2/cycle) or carboplatin ( 250 mg/m2/cycle). The interval between the cycles should be less than or equal to 4 weeks. For other dose-regimens a total accumulative dose of cisplatin 120 m2g/m2 or carboplatin 500 mg/m2 given within a maximum of 8 weeks is acceptable (dose-intensity 15 mg/m2/week for cisplatin and 62 mg/m2/week for carboplatin).
Platinum-based chemotherapy may have been given as monotherapy or in combination with other chemotherapy agents (e.g. 5-fluorouracil (5FU)) and/or radiation.
Failure is defined as (a) refractory or (b) intolerant to a standard platinum-based chemotherapy as follows:
a. Refractory is defined as disease progression according to RECIST during one course of standard platinum-based chemotherapy or within 6 months after completion of one course of standard platinum-based chemotherapy, given as treatment of • non-metastatic disease when platinum-based chemotherapy was given with a curative intention • metastatic disease • relapse not amenable for curative intervention
b. Intolerant is defined as discontinuation of one course of platinum-based chemotherapy due to side effects/toxicity irrespective of response
Patients must have disease progression according to RECIST, documented with two CT scans or MR images;
1) If a patient has obtained a response according to RECIST after standard platinum based chemotherapy the patient is eligible if a progression is confirmed within 6 months following standard platinum based chemotherapy. Disease progression should be documented with: • a scan/image acquired at response after standard platinum-based chemotherapy or a scan/image acquired before standard platinum based chemotherapy and • a scan/image acquired within 6 months after standard platinum based chemotherapy
2) If a patient has obtained no response after platinum based chemotherapy Disease progression should be documented with • a scan/image acquired before standard platinum based chemotherapy and • a scan/image acquired within 6 months after standard platinum based chemotherapy.
In both situations the scan taken at the screening visit for this trial may serve as the progression scan if it is performed within 6 months after standard platinum based chemotherapy.
4) Measurable disease defined as one or more target lesions according to RECIST.
5) WHO performance status ≤ 2.
6) Following receipt of verbal and written information about the study, the patient must provide signed informed consent before any study related activity is carried out.
|
|
E.4 | Principal exclusion criteria |
1) Three or more prior chemotherapy regimens
2) Prior treatment with EGFr antibodies and/or EGFr small molecule inhibitors
3) Received the following treatments within 4 weeks prior to Visit 2:
Cytotoxic or cytostatic anti-cancer chemotherapy Other immunosuppressive drugs (e.g. drugs interfering with the functions of T cells, IL-2 or equivalent) Total tumor resection
4) Past or current malignancy other than SCCHN, except for:
Cervical carcinoma Stage 1B or less Non-invasive basal cell and squamous cell skin carcinoma Malignant melanoma with a complete response of a duration of > 10 years Other cancer diagnoses with a complete response of a duration of > 5 years
5) Chronic or current infectious disease, such as, but not limited to, chronic renal infection, chronic chest infection with bronchiectasis, sinusitis, and tuberculosis. Exempted are secondary infections in tumor lesions.
6) Known brain metastasis or leptomeningeal disease.
7) Clinically significant cardiac disease including unstable angina, acute myocardial infarction within six months from Visit 1, congestive heart failure, and arrhythmia requiring therapy, with the exception of extra systoles or minor conduction abnormalities
8) Significant concurrent, uncontrolled medical condition including, but not limited to, renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease evaluated by the investigator to interfere with effect of the study drug
9) Expected survival < 3 months.
10) Known HIV positive
11) Known hepatitis B and/or C
12) Screening laboratory values:
WBC < 3.0 x10E9/L Neutrophils < 1.5 x10E9/L Platelets < 75 x10E9/L ALAT > 2.5 times the upper limit of normal (unless known liver metastases) ALP > 2.5 times the upper limit of normal (unless known bone metastases) Bilirubin > 1.5 times the upper limit of normal Creatinine > 1.5 the upper limit of normal.
13) Patients who have received treatment with any non-marketed drug substance within 4 weeks prior to Visit 1 (screening)
14) Current participation in any other interventional clinical study
15) Patients known or suspected of not being able to comply with this trial protocol
16) Breast feeding women or women with a positive pregnancy test at Visit 1.
17) Women of childbearing potential not willing to use adequate contraception as hormonal birth control or intrauterine device, during study and 12 months after last dose of HuMax-EGFr.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Overall Survival (OS) defined as the time from randomization until date of death from any cause. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 62 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
An interim statistical analysis will be performed when 116 deaths have been observed with a possibility of early stopping. If the hazard ratios required to show significance are not met when the interim analysis is performed, the trial will end when 236 deaths have been observed. The maximum number of patients to be recruited is 273.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |